Antibody Information
General Information of This Antibody
| Antibody ID | ANI0KXEJB |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-Lewis-Y mAb G193 |
|||||
| Organization | Wyeth AB; Pfizer Inc. |
|||||
| Synonyms |
Anti-Lewis-Y mAb G193
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antigen Name | Lewis Y |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CMD-193 [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Complete Remission (CR) |
0.00%
|
|||
| Patients Enrolled |
Patients with advanced tumours expressing the Lewis-Y antigen.
|
||||
| Administration Dosage |
111-In-CMD-193 iv then 1.00 mg/m^2, 2.60 mg/m^2 iv of CMD-193.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00293215 | Clinical Status | Phase 1 | ||
| Clinical Description |
Biodistribution study of cmd-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Patients with advanced malignant tumors.
|
||||
| Administration Dosage |
CMD-193 iv.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00257881 | Clinical Status | Phase 1 | ||
| Clinical Description |
Phase 1 biodistribution study of 111-indium-CMD-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Patients with advanced malignant tumors.
|
||||
| Administration Dosage |
CMD-193 iv.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00161642 | Clinical Status | Phase 1 | ||
| Clinical Description |
Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.00% (Day 100) | Positive Lewis-Y expression (Lewis-Y +++/++) | ||
| Method Description |
hu3S193-CalichDMH (4 ug) induces efficient tumor cell killing in cell line-derived models of PV-1 cells with CD28 expression.
|
||||
| In Vivo Model | N193 CDX model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
References